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Objective. Ovarian carcinomas are presumed to arise within ovarian inclusion cysts or from a coexisting epithelial lesion in the
ovary. Insight may be gained by relating diﬀerent subtypes of ovarian cancer with the presence of coexisting tumor-like conditions.
Methods. The Dutch nation-wide pathology database PALGA (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief)
identiﬁed the various histopathological subtypes of ovarian cancer in 824 patients diagnosed in 1996–2003, and recorded the
presence of epithelial tumor conditions around the ovarian tumors. In addition, a PALGA database of all 153 consecutive patients
referred to the Nijmegen University Medical Centre in 2007 for histopathological work-up was analyzed. Results.T h ep r e v a l e n c e
of coexisting ovarian tumor conditions was 16.4% (135 out of 824 patients, (95%CI:8.4%–24.4%)). The coexistence was highest
for endometrioid, mucinous, clear cell, and borderline malignancies. The referral group revealed 35% (54 out of 153 patients,
(95%CI:28%–42%)) of coexisting epithelial ovarian tumor conditions. Conclusion. One in six patients with a malignant ovarian
tumor has a coexisting epithelial tumor condition in the ovary, which is also rather frequently observed in the diagnostic work-up
practice.
1.Introduction
In developed countries, ovarian cancer is a commonly
occurring neoplasm, ranking the 7th and 6th most frequent
position for incidence and mortality, respectively [1]. High-
incidence areas are Europe and North America, making it an
important public health issue [2].
Epithelial ovarian tumors are thought to arise from
the surface epithelium (mesothelium) of the ovary [3].
Most early-stage ovarian cancer produce no symptoms, and
therefore the majority of the patients present with advanced
disease, making prognosis poor. So far, pathologists have
devoted very little attention to early ovarian cancer originat-
ing in a coexisting benign epithelial lesion [4]. The precise
origin of this epithelium is controversial; one hypothesis
argues that the mesothelium lining of the ovarian surface
undergoesaM¨ ullerianmetaplasia;anotheronethatthesame
epithelium is derived from the fallopian tube or uterus via
passive transport [5].
There are four main types of epithelial ovarian cancer:
serous ovarian carcinoma (30% to 70%), mucinous ovarian
carcinoma (5% to 20%), endometrioid ovarian carcinoma
(10% to 20%), clear cell carcinoma (3% to 10%), and
furthermore a minor group of transitional cell or Brenner
tumor (1%), and mixed epithelial carcinoma (3%) [6–8]. As
described by Mok et al. [9] the progression model of epithe-
lial ovarian cancer is complicated, when the diﬀerent histo-
logical subtypes of ovarian neoplasms are considered. One
theory is that ovarian carcinoma arises from endometriosis,
the ectopic occurrence of endometrial tissue [10]. Especially
clear cell and endometrioid carcinomas are thought to
arise from foci of endometriosis [11]. Associations between
endometriosis and ovarian carcinoma have been found,
but could also be explained by shared risk factors for the
coexistence of the conditions [11].
The ovarian surface epithelium (OSE) is generally
regarded as the precursor of epithelial ovarian tumors. Re-2 ISRN Obstetrics and Gynecology
centevidence,however,suggeststhatthefallopiantubecould
also be the source of some subtypes of epithelial ovarian
cancers [12]. Since the ovaries and tubes are closely related,
it is hypothesized that cells of the tubes can mimic ovarian
cancer [13, 14].
The aim of this study is to investigate the coexistence
of diﬀerent epithelial subtypes of ovarian carcinoma, with
tumor-like conditions [15], benign tumors, and borderline
malignancies, in relation to age under and above 55 years at
diagnosis, as an approach to distinguish the development of
pre- and postmenopausal pathways.
2.MaterialsandMethods
We used a random sample (1000 patients out of 9000
patients) out of the database of the nation-wide pathology
database PALGA in the Netherlands [16] of the years 1996–
2003,fromwhich824patientsappearedtobediagnosedwith
an epithelial ovarian cancer. Records in the PALGA database
contain comprehensive summaries of the pathology reports
and diagnostic codes similar to the systematized nomencla-
ture of medicine (SNOMED) classiﬁcation of the College
of American Pathologists [16]. We scrutinized all reports of
20 lines on average, (>250 words) of the random sample of
1000 patients with an ovary-related diagnosis. Of these 824
patients, with an epithelial ovarian malignancy we collected
all other records from PALGA linked with histopathological
conﬁrmed diagnoses of borderline malignancies, benign
tumors, and tumor-like conditions (endometriosis, simple
cysts, endometriotic cysts, and inclusion cysts (two ruptured
cysts and one cyst wall)) in the ovary. In case of a diagnose of
borderlinemalignancyaswellasmalignantcarcinoma,inthe
same patient, the borderline tumor was seen as a coexisting
condition.
Considering the impact of the ﬁndings to current
medical practice, we also studied all PALGA receipts of
the PALGA database of the pathology department at the
Radboud University Nijmegen Medical Centre. It contained
the records of 153 patients diagnosed with an ovary-related
diagnosis. The Scientiﬁc Committee of PALGA approved the
study protocol.
2.1. Data Analyses. Descriptive analysis was applied to learn
from the association between histopathologically subtypes
of ovarian epithelial cancer and benign epithelial neo-
plasms and tumor-like conditions. Anticipating diﬀerent
developmental pre/postmenopausal pathways from benign
tomalignanttumors,ageatdiagnosiswasdichotomizedat55
year. The Chi-square test was used to arrive at P-values, and
95% conﬁdence intervals for proportions were calculated.
3. Results
We studied 824 patients with ovarian tumor; 806 had
malignant carcinomas and 18 had borderline lesions without
carcinomalesions.In135women(16.4%)coexistingovarian
cancer lesions were observed (95% CI: 8.4%–24.4%). In
21 patients two diﬀerent types of coexisting ovarian tumor
lesions or tumor-like conditions were noticed. Of the 806
patientswithmalignantovariancancer,129patients(16.0%)
had also a tumor-like condition (n = 38), a benign tumor
(n = 47), or a borderline malignancy (n = 44). Of
the 18 patients with borderline malignancies, 6 (33.0%)
had coexisting lesions. The presence of possible precursors
according to the diﬀerent histological subtypes and for both
age categories is shown in Table 1. Coexisting epithelial
tumor conditions were more prevalent in the age category
<55 years. Overall, the ratio of the prevalences of the under
age 55 versus 55+ group was 1.71 (95% CI: 1.26–2.31). In
particular the subtypes of endometrioid, mucinous, clear
cell, and borderline malignancies showed excess prevalences
for women under age 55 years.
Of the 153 consecutive patients from the Department
of Pathology of the UMCN in 2007, 54 out of 153
patients did not have coexisting ovarian tumor conditions
or abnormalities. A number of 22 patients had nonepithelial
lesions while for two lesions it could not be established
whether the tumors were primarily linked to the ovaries or
were metastases from elsewhere. The remaining 75 records
concerned epithelial ovarian lesions ranging from tumor-
like conditions (inclusion cysts and simple cysts n = 29),
adenomas (n = 15), borderline malignancies (n = 6), to
malignant tumors (n = 25); see Table 2. One-third were
actually cancer, mainly serous carcinomas and adenocarci-
nomas not otherwise speciﬁed, of which 4 patients (16.0%)
also showed coexisting epithelial tumor lesions or tumor-
like conditions. This means that the hospital referral group
revealed 35% (54 out of 153 patients) of coexisting epithelial
ovarian tumor conditions.
Of the lesions considered as coexisting epithelial tumor
conditions, 58.0% (29/50) were tumor-like conditions,
40.0% (15/50) adenomas, and 12.0% (6/50) borderline
malignancies. Of the carcinoma patients (25), 32.0% were
youngerthan55yearsoldwhileoftheborderlinemalignancy
patients67.0%(6/10)wereyoungerthan55.Ofpatientswith
adenomas or tumor-like conditions, 80.0% and 82.8% were
under age 55 (Table 2).
Coexisting conditions were almost similar to the princi-
ple ovary cancer in case of borderline malignancies (83%)
and less similar in the other types of malignancies (46–64%).
4. Discussion
4.1.ThePALGADatabase1996–2003. Oneoutofsixpatients
with a malignant epithelial ovarian cancer did have a
coexisting ovarian benign lesion. Tumor-like conditions and
adenomas were the most commonly observed benign lesions
whereas serous, endometrioid, and mucinous carcinomas
were the most common malignant tumors. Tumor-like
conditions,especiallyinendometrioidcarcinomas,werevery
frequent (data not shown). One in three of these cases was
an endometrioid cyst or endometriosis. The actual number
of endometrioid cysts may have been even larger, indicating
a relation between endometriosis, endometrioid cyst and
endometrioid carcinoma [9, 11, 17]. Nevertheless, because
of the cross-sectional nature of our study, causality cannot
be deferred, which means that this relation may also be
explained by shared risk factors [11].ISRN Obstetrics and Gynecology 3
Table 1: The occurrence of coexisting ovarian tumor conditions in epithelial ovarian cancer according to subtypes and the age at diagnosis
in 824 patients.
Ovarian cancer subtype and age category Total 1 or 2 lesions present∗
Ratio of prevalences (95% CI)
nn %∗
All subtypes 824 135 16.4
<55yr 274 62 22.6 1.71 (1.26–2.31)
≥55yr 550 73 13.3 1
Serous carcinoma 385 42 10.9
<55yr 113 15 13.3 1.33 (0.74–2.42)
≥55yr 272 27 9.9 1
Endometrioid carcinoma 113 25 22.1
<55yr 46 13 28.3 1.58 (0.79–3.14)
≥55yr 67 12 17.9 1
Mucinous carcinoma 98 28 28.6
<55yr 47 16 34.0 1.45 (0.76–2.73)
≥55yr 51 12 23.5 1
Adenocarcinoma 73 12 16.4
<55yr 17 3 17.6 1.10 (0.33–3.60)
≥55yr 56 9 16.1 1
Clear cell carcinoma 56 11 19.6
<55yr 23 7 30.4 2.51 (0.83–7.60)
≥55yr 33 4 12.1 1
Mixed malignancy 34 5 14.7
<55yr 11 2 18.2 1.39 (0.27–7.18)
≥55yr 23 3 13.0 1
Borderline malignancy 18 6 33.3
<55yr 11 4 36.4 1.27 (0.31–5.20)
≥55yr 7 2 28.6 1
Other 47 6 12.8
<55yr 6 2 33.3 3.41 (0.79–14.80)
≥55yr 41 4 9.8 1
∗Lesions present: tumor-like condition (endometriosis, simple cysts, endometriotic cysts, inclusion cysts), benign tumor, and borderline malignancy.
95% CI, conﬁdence interval.
Table 2: Speciﬁc diagnoses of 75 consecutive tissue specimen from
PALGA Nijmegen 2007 according to age.
Diagnosis All ages <55yr ≥55yr
nn % n %
Total 75 48 64.0 27 36.0
Ovarian carcinoma 25∗ 8 32.0 17 68.0
Borderline malignancies 6 4 66.6 2 33.3
Adenoma 15 12 80.0 3 20.0
Tumor-like conditions∗∗ 29 24 82.8 5 17.2
∗4 patients (16.0%) showed coexisting epithelial ovarian tumor conditions.
∗∗tumor-like conditions: simple cysts, endometriotic cysts, inclusion cysts.
Coexisting epithelial ovarian carcinoma conditions: (4 + 6 + 15 + 29)/75 =
72%.
Chi-square = 17.225, df = 3, P-value = 0.001.
Ovarian cancer patients who had a malignant as well as a
benign lesion were generally younger than women with only
a malignant tumor. This may underpin the fact that benign
tumors tend to occur at younger age than malignant tumors.
As stated earlier, only part of the malignant epithelial
ovarian tumors will arise from a coexisting benign epithelial
lesion [4, 18]. As endometrioid, mucinous, clear cell, and
borderline malignant epithelial tumors are more common in
women with a benign and a malignant lesion, these subtypes
are the most likely to develop through tumor transition.
Recently it is hypothesized that most high-grade serous
carcinomas (50% or more) arise from the distal fallopian
tube (ﬁmbria) [19]. Our results may not be in conﬂict with
this hypothesis while only a small number (10.9%) of serous
carcinomas had coexisting lesions. A subset will develop de
novo from the ovarian surface epithelium or its inclusion
cysts [20].
As described by Auersperg et al. [21] the surface epithe-
lium of the ovary and tubal epithelium were considered as
a unit, with an area of increased susceptibility to neoplastic
progression encompassing the ovarian surface epithelium
andthedistalﬁmbriae.Progressionalongdiﬀerenthistotypic
pathways might then be inﬂuenced by microenvironmental
factors and mutational events.
4.2. Findings of the PALGA Nijmegen 2007 Database. Women
with a tumor-like condition or adenoma appeared to be
younger (82.8% at age <55 year and 80.0%, resp.) than4 ISRN Obstetrics and Gynecology
women with a malignant tumor (32.0% at age <55 years).
The majority of patients with a borderline malignancy also
were younger than 55 years (66.6%).
Describing the occurrence of benign ovarian tumors in
itselfisalsoverydiﬃcult. Asstatedearlier, malignantovarian
tumors are often diagnosed in a late stage; benign tumors
are often not detected at all, for example, when an obvious
carcinoma is present within the ovary, most pathologists
would not mention the presence of cortical inclusion cysts.
Therefore, in daily gynecological practice most of the benign
tumors may be detected coincidentally. This, however, only
seemstobethetipoftheiceberg:mostbenigntumorsremain
undetected. Consequently, it is hard to study at which age
what kind of benign tumors occur.
A limitation of the PALGA Nijmegen 2007 database was
that it was unclear whether the patients without abnormality
or benign lesion were representing the general population.
Some of the patients had the ovaries removed because they
were carriers of a mutation in BRCA1 or BRCA2, which sets
them at high risk to develop ovarian cancer. Other patients
were examined because they had symptoms. Due to this fact,
the incidence of benign lesions is probably higher than in the
general population. It is unknown whether the larger dataset
also contains BRCA/high-risk women as well.
5. Conclusion
The strength of this study is the analysis speciﬁed to the var-
ious histological subtypes in relation to possible precursors
of ovarian cancer and malignancies. Overall, the prevalence
of coexisting epithelial ovarian tumor conditions was 1.71-
times (95% CI: 1.26–2.31) as high in patients <55 years
versus patients ≥55 years. Unfortunately, sparse numbers of
cases hamper to arrive at a meaningful conclusion on more
aggressive malignancies in younger women. The histological
subtypes endometrioid, mucinous, clear cell, and borderline
malignancies showed the highest prevalences of coexisting
lesions.
Weaknesses of the study lie in its retrospective design and
the fact that coexisting pathologies are usually overlooked
or better said underreported. Further research is needed to
conﬁrm the results in larger study populations, and possibly
be combined with a study of (pre-)neoplasia arising in the
Fallopian tube in relation to the hereditary serous ovarian
carcinogenesis hypothesis from Piek [13].
The analysis of the PALGA Nijmegen 2007 database
indicates that half of all patients referred to the University
Medical Centre St. Radboud with tissue specimen sent to
the pathology department, have epithelial ovarian tumor
conditions. Two-thirds of the latter seem to have coexisting
epithelial tumor conditions, adding to the progression to
the malignant disease stage. These ﬁndings may prompt to
not only reporting ovary cancer but also coexisting ovarian
tumor conditions. The latter if detected in the absence of
ovary cancer need follow-up surveillance.
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